SeqLL (NASDAQ:SQL – Get Rating) is one of 41 publicly-traded companies in the “Analytical instruments” industry, but how does it compare to its rivals? We will compare SeqLL to similar companies based on the strength of its risk, dividends, analyst recommendations, earnings, profitability, institutional ownership and valuation.
Earnings and Valuation
This table compares SeqLL and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|SeqLL Competitors||$1.15 billion||$357.41 million||-54.22|
SeqLL’s rivals have higher revenue and earnings than SeqLL. SeqLL is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
SeqLL currently has a consensus price target of $3.00, suggesting a potential upside of 552.60%. As a group, “Analytical instruments” companies have a potential upside of 16.44%. Given SeqLL’s stronger consensus rating and higher possible upside, equities research analysts plainly believe SeqLL is more favorable than its rivals.
Institutional & Insider Ownership
0.1% of SeqLL shares are owned by institutional investors. Comparatively, 52.1% of shares of all “Analytical instruments” companies are owned by institutional investors. 22.3% of SeqLL shares are owned by insiders. Comparatively, 15.8% of shares of all “Analytical instruments” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
This table compares SeqLL and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
SeqLL has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Comparatively, SeqLL’s rivals have a beta of 1.03, meaning that their average stock price is 3% more volatile than the S&P 500.
SeqLL rivals beat SeqLL on 7 of the 13 factors compared.
SeqLL Company Profile
SeqLL Inc. operates as a life sciences instrumentation and research services company worldwide. The company designs, develops, and manufactures genetic analysis technologies. It offers true single molecule sequencing (tSMS) platform, which offers a single molecule solution for DNA and RNA sequencing. The company has a collaboration agreement with Bernstein Laboratory, Ting Laboratory, The Jackson Laboratory for Genomic Medicine, Weizmann Institute of Science, True Bearing Diagnostics, Inc., and Tetracore, Inc. It serves academic and government institutions, hospitals and medical centers, pharmaceutical and biotechnology companies, and non-profit research organizations. The company was founded in 2013 and is based in Billerica, Massachusetts.
Receive News & Ratings for SeqLL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SeqLL and related companies with MarketBeat.com's FREE daily email newsletter.